| __timestamp | Ligand Pharmaceuticals Incorporated | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 22570000 | 7751000 |
| Thursday, January 1, 2015 | 24378000 | 10251000 |
| Friday, January 1, 2016 | 26621000 | 9575000 |
| Sunday, January 1, 2017 | 28653000 | 10912000 |
| Monday, January 1, 2018 | 37734000 | 11049000 |
| Tuesday, January 1, 2019 | 41884000 | 11646000 |
| Wednesday, January 1, 2020 | 64435000 | 13265000 |
| Friday, January 1, 2021 | 57483000 | 25805000 |
| Saturday, January 1, 2022 | 70062000 | 35182000 |
| Sunday, January 1, 2023 | 52790000 | 94999000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical industry, understanding spending patterns is crucial for strategic planning. Ligand Pharmaceuticals and Viridian Therapeutics, two prominent players, have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Ligand Pharmaceuticals experienced a steady increase in SG&A expenses, peaking in 2022 with a 210% rise from 2014. However, 2023 saw a 25% decline, indicating potential cost optimization or strategic shifts. In contrast, Viridian Therapeutics displayed a more volatile pattern, with a dramatic 1,125% surge in 2023 compared to 2014, reflecting aggressive expansion or increased operational activities. This comparative analysis highlights the dynamic nature of financial strategies within the pharmaceutical sector, offering insights into how companies adapt to market demands and internal objectives.
Breaking Down SG&A Expenses: GSK plc vs Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of argenx SE and Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
SG&A Efficiency Analysis: Comparing Biogen Inc. and Ligand Pharmaceuticals Incorporated
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Viridian Therapeutics, Inc.
Selling, General, and Administrative Costs: Bio-Techne Corporation vs Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Alpine Immune Sciences, Inc. or Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Perrigo Company plc and Viridian Therapeutics, Inc.
Xenon Pharmaceuticals Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Amicus Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Amphastar Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Xencor, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared